Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Subscribe To Our Newsletter & Stay Updated
